Request Demo

Last update 08 May 2025

Intravitreal ranibizumab(Sultan Qaboos University Hospital)

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Fab fragment, Biosimilar

Synonyms

Intravitreal ranibizumab(Sultan Qaboos University Hospital), Ranibizumab biosimilar (Sultan Qaboos University Hospital), 雷珠单抗生物类似药 (Sultan Qaboos University Hospital)

Target

VEGF-A

Action

inhibitors

Mechanism

VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)

Therapeutic Areas

Congenital DisordersEye Diseases

Active Indication

Retinal Dysplasia

Inactive Indication

Biallelic RPE65 mutation associated retinal dystrophy

Originator Organization

Sultan Qaboos University Hospital

Active Organization

Sultan Qaboos University Hospital

Inactive Organization

University of Sultan Qaboos

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure/Sequence

Sequence Code 103170L

The sequence is quoted from: *****

Sequence Code 143622H

The sequence is quoted from: *****

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	S01LA04	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Biallelic RPE65 mutation associated retinal dystrophy	Phase 2	-	University of Sultan Qaboos	24 Jul 2015
Retinal Dysplasia	Phase 2	-	Sultan Qaboos University Hospital	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2024	Not Applicable	Retinopathy of Prematurity	131	Intravitreal injection of Ranibizumab 0.25 mg/0.025 ml	hswtibmvea(iltmfzbwgz) = fiomebybiz mxkpcmmlkb (roetinzwuv, 1.37) View more	Positive	19 Sep 2024
ARVO2023	Not Applicable	Retinopathy of Prematurity First line	44	Intravitreal ranibizumab 0.2 mg	athgyydivz(akpryonrjt) = jkbgswvcho nxmrjvcgnu (eayrgihyjz ) View more	-	01 Jun 2023
APAO2023	Not Applicable	Myopic choroidal neovascularization	14	Intravitreal Ranibizumab Injection	(majhwrtyej) = oaphzcuvvw rdzentdlhc (bnotkcvfzn ) View more	Positive	23 Feb 2023
EURETINA2022	Not Applicable	Wet age-related macular degeneration	-	Intravitreal ranibizumab (0.5 mg)	lpnvsjdcnp(qhjajwjsfx) = decrease of PWV after the first (by 0.34 m/s) and the second injection (by 0.31 m/s) and remained decreased 1 month after the third injection (overall P<0.05) dfzwmjwnrf (whtcpwnubw ) View more	-	01 Sep 2022
EURETINA2022	Not Applicable	Wet age-related macular degeneration	-	Placebo		-	01 Sep 2022
EURETINA2022	Not Applicable	Diabetic macular oedema \| Wet age-related macular degeneration	-	Intravitreal Ranibizumab Biosimilar	(bxaaszgetn) = zqrexnatnp ufocgfisxd (ildyeywefs ) View more	Positive	01 Sep 2022
APAO2021	Not Applicable	Retinal Vein Occlusion	81	Intravitreal Ranibizumab Monthly	(zlyiltisaz) = cbspfybwkj rwliepudcw (pkjmqputjz, 193.18)	Positive	05 Sep 2021
APAO2021	Not Applicable	Retinal Vein Occlusion	81	Intravitreal Ranibizumab PRN	(zlyiltisaz) = nxbutxixuo rwliepudcw (pkjmqputjz, 108.92)	Positive	05 Sep 2021
APAO2021	Not Applicable	Choroidal Neovascularization	-	Intravitreal Ranibizumab Monthly Protocol	oojgxycglb(qckckttgjk) = onncipsayx ggwcmddtnd (zfdfamwjpv ) View more	-	05 Sep 2021
APAO2021	Not Applicable	Choroidal Neovascularization	-	Intravitreal Ranibizumab PRN Protocol	oojgxycglb(qckckttgjk) = sercpaznam ggwcmddtnd (zfdfamwjpv ) View more	-	05 Sep 2021
APAO2021	Not Applicable	Diabetic Retinopathy	-	Monthly Intravitreal Ranibizumab	csckxmptno(bxijemjzgo) = xczgfqmrtd tssbgaovbs (hfibmtdhul, 73.25)	-	05 Sep 2021
APAO2021	Not Applicable	Diabetic Retinopathy	-	Pro Re Nata (PRN) Intravitreal Ranibizumab	csckxmptno(bxijemjzgo) = jahdkeensu tssbgaovbs (hfibmtdhul, 63.05)	-	05 Sep 2021
EURETINA2021	Not Applicable	Retinal vein occlusion-related macular edema	-	Intravitreal injection of Ranibizumab	(ioxiqcklok) = amjhxzwfyz cmarsujrdh (ruekdnwgdd ) View more	-	01 Sep 2021
ARVO2018	Not Applicable	Diabetic macular oedema	22	Intravitreal ranibizumab 0.3 mg	eufanidfge(lpflyctzri) = bthjqxbdoz eyadlgcgoa (pgmiimemno, 0.20) View more	-	01 Jul 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis